The compound is typically provided as a lyophilized peptide formulation to maintain structural stability during transport and storage
Certain groups have been excluded from trials or may face additional risks, including: People who are pregnant or breastfeeding , as the safety profile in these groups has not been established Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) this exclusion reflects trial protocols and the US prescribing label for some GLP-1 receptor agonists
By year 2, headache rates were identical in both groups, indicating that the medication-related excess seen in shorter trials doesnt persist long term
Recently, some people have started microdosing GLP-1 medicines by taking less than the recommended dosage
In many trials, the headache rate in treated participants does not exceed expected background rates, which argues against a strong causal effect across broad populations
Tirzepatide may cause slightly stronger digestive symptoms early due to its dual-hormone action, while semaglutide may feel milder for some patients at first
